

## Special Issue

# Predicting Psychopathological Onset: Early Signs of Neuropsychiatric Diseases

### Message from the Guest Editor

Millions of people worldwide are affected by neuropsychiatric disorders, such as anxiety, major depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder, and post-traumatic stress disorder. Although clinical tools are valuable in treating psychopathologies, the identification of early signs of psychopathology remains a main target to be reached in order to improve treatment effectiveness and reduce poor outcomes. The assessment of biological, behavioural, and cognitive markers of psychopathology could provide a significant support in pre-clinical phases to identify vulnerability factors, understand the course of illness and predict its outcome, as well as aid clinicians in the therapeutic decision-making process. In this Special Issue of the *Journal of Personalized Medicine*, papers addressing early markers of psychopathology aimed at improving diagnostic tools and at envisaging personalized therapies are welcome.

### Guest Editor

Dr. Marco Costanzi

Department of Human Sciences, Lumsa University, 00100 Rome, Italy

### Deadline for manuscript submissions

closed (10 December 2021)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/47775](https://mdpi.com/si/47775)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).